Isa Mourushi, Ramos Ma Rosario Rufina, Kamal Shahed
General Medicine, Northern Health, Melbourne, AUS.
Medicine, Ateneo School of Medicine and Public Health, Pasig, PHL.
Cureus. 2025 Mar 15;17(3):e80634. doi: 10.7759/cureus.80634. eCollection 2025 Mar.
Rheumatology patients on biological disease-modifying anti-rheumatic drugs (bDMARDs) have been proposed to be at a higher risk of infections. Our review summarizes the current evidence behind this theory as well as explores which factors predispose patients to various infections, which agents are more likely to cause infections, and which infections are common in these patients. We also aim to explore updated guidelines on infection prevention in patients on bDMARDs.
有观点认为，使用生物性改善病情抗风湿药（bDMARDs）的风湿病患者感染风险更高。我们的综述总结了这一理论背后的现有证据，并探讨了哪些因素使患者易发生各种感染、哪些药物更易导致感染以及这些患者中常见哪些感染。我们还旨在探索bDMARDs治疗患者感染预防的最新指南。
